BCLI
BRAINSTORM CELL THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$0.77
−1.17%Next report
Analyst consensus
- Next report date
- Nov 16, 2026
- EPS estimate
- -$0.18
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.35
- EPS estimate
- -$0.29
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -26.0%
- Revenue beats (12Q)
- —
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.29 | -$0.35 | Miss -20.69% | — |
| May 15, 2026 | -$0.28 | -$0.19 | Beat 32.14% | — |
| Mar 31, 2026 | -$0.36 | -$0.20 | Beat 44.44% | — |
| Nov 14, 2025 | -$0.35 | -$0.91 | Miss -160.00% | — |
| Aug 14, 2025 | -$0.41 | -$0.34 | Beat 17.07% | — |
| May 15, 2025 | -$0.97 | -$0.45 | Beat 53.61% | — |
| Mar 31, 2025 | -$0.49 | -$0.51 | Miss -4.08% | $849.0K |
| Nov 14, 2024 | -$0.45 | -$1.80 | Miss -300.00% | — |
| Aug 14, 2024 | -$0.60 | -$0.60 | In line | — |
| Apr 1, 2024 | -$2.25 | -$1.65 | Beat 26.67% | $343.0K |
| Nov 14, 2023 | -$2.10 | -$2.10 | In line | — |
| Aug 14, 2023 | -$2.25 | -$1.95 | Beat 13.33% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 16, 2026